Day: July 31, 2025

Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth RUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribers Joenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptake Second quarter operating profit amounted to US$10.8 million compared to a US$3.1 million loss in the second quarter 2024 Study published in leading peer-reviewed journal Cell identifies new variants leading to PI3Kδ pathway hyperactivity, supporting reclassification of VUS patients to APDS and suggesting up to a 100-fold increase in APDS prevalence Submitted...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRSECOND QUARTER/FIRST HALF YEAR | 2025Q2 2025 sales of CHF 968 million were flat in local currencies1, as growth in Catalysts and Adsorbents & Additives offset a slight decline in Care Chemicals; stable pricing Q2 2025 EBITDA margin before exceptional items increased by 200 basis points to 17.5 % from 15.5 % in Q2 2024, driven by improvements in Catalysts and Adsorbents & Additives, while flat in Care Chemicals; reported EBITDA margin impacted by CHF 22 million restructuring charges H1 2025 sales increased by 1 % in local currencies1 to CHF 1.981 billion, as growth in Care Chemicals and Adsorbents & Additives offset slightly lower Catalysts sales; pricing was up 1 % H1 2025 EBITDA margin before exceptional items increased by 130 basis points to 18.1 % from 16.8 % in the...

PRESS RELEASE Arcadis Second Quarter and Half Year Results 2025 Strong margin, well positioned for growth KEY HIGHLIGHTSNet revenues were €1,937 million: stable year-on-year on an organic basis Increased Key Client order intake further improving backlog quality (3% ytd organic growth) Strong operating EBITA margin of 11.3% in the quarter, with substantial strategic investments to accelerate future growth and further cost efficiencies Integration of recently acquired WSP Rail and KUA Data Centers unlocking new growth opportunities in Germany Well positioned for growth in the second half of 2025: large contracts ramping up, increased UK spending and improved market stabilityAmsterdam, 31 July 2025 – Arcadis, the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and...

Press ReleaseKaiseraugst (Switzerland), Maastricht (Netherlands), July 31, 2025 dsm-firmenich reports H1 2025 results Management Report H1 2025 highlightsGood first half of the year, with good organic sales and earnings growth Progressing well on 2025 strategic plan Completion of sale of Feed Enzymes business for €1.5 billion on June 2, 2025 €1 billion share buyback program commenced in April 2025, and completion accelerated to January 2026 Animal Nutrition & Health exit process advancing FY 2025 outlook updated: Adjusted EBITDA around €2.4 billionKey figuresin € millions H1 2025 H1 2024 % Change Q2 2025 Q2 2024 % ChangeSales 6,510 6,298 3 3,236 3,227 0Organic sales growth (%) 7     6    Adj. EBITDA 1,260 976 29 610 513 19Adj. EBITDA margin (%) 19.4 15.5   18.9 15.9  Net profit (total group) 541 50 982      Core...

Regulated informationRevenue drop by 4% in H1, caused mainly by weak baby care demand in Europe; Adj. EBITDA margin down by 2.2pp in H1, due to lower fixed cost absorption caused by lower volumes, and a rising cost environment; Expecting low single digit revenue contraction for full year 2025 and adj. EBITDA in €200-210 million range.CEO quote Gustavo Calvo Paz, Ontex’s CEO, said: “The weak first half of the year, while disappointing, will not derail us from our strategic journey. We are steadily progressing and deliver results step by step. The reshaping of the portfolio and the strengthening of the balance sheet have been largely realized. The innovation pipeline has been strengthened and will continue to deliver. Our business in North America has demonstrated fast growth, on the pursuit of scale, and we have taken major steps toward...

H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in OncologyH1 core operating income of €656m, growing by 21.9% as reported, with a core operating margin of 36.0% of total sales, increasing by 3.6 pointsUpgraded FY 2025 financial guidance2: total-sales growth greater than 7.0% at CER (prior guidance: greater than 5.0% at CER); core operating margin greater than 32.0% of total sales (prior guidance: greater than 30%)Pipeline progression including regulatory filing of tovorafenib in Europe, and initiation of a Phase II trial of LANT3 (IPN10200) in cervical dystoniaEuropean Commission approval on 23 July 2025 of Cabometyx® in advanced neuroendocrine tumors (NETs), the sixth indicationKey upcoming milestones with the pivotal...

Press release31 July 2025 – N° 11 Second quarter 2025 results                 EUR 226 million net income in Q2 2025, contributing to a EUR 425 million net income in H1 2025Group net income of EUR 226 million in Q2 2025 driven by all business activities (EUR 225 million adjusted1) P&C combined ratio of 82.5% with benign natural catastrophe experience and excellent attritional loss performance allowing for additional buffer building L&H insurance service result2 of EUR 118 million, with H1 experience variance in line with expectations Investments regular income yield of 3.5%, with continued attractive reinvestment ratesIFRS 17 Group Economic Value3 of EUR 8.5 billion as of 30 June 2025, up +10.5%4 at constant economics5 (down -1.7% on a reported basis) compared with 31 December 2024, implying an Economic Value...

ING posts 2Q2025 net result of €1,675 million, with strong growth in lending volumes and fee income 2Q2025 profit before tax of €2,369 million with a CET1 ratio of 13.3%• Well on track to reach our targets, one year into our ‘Growing the difference’ strategy• Continued strong increase in mobile primary customers of over 300,000 to 14.9 million• Resilient total income, supported by higher customer balances, with particularly strong growth of our mortgage portfolio• Further growth in fee income in both Retail and Wholesale Banking, up 12% year-on-year• ING will pay an interim cash dividend of €0.35 per ordinary share  CEO statement“During the second quarter of 2025, we have continued to successfully execute our strategy, which...

  Half-Year 2025 results Solid results driven by digital and a uniquegeographic footprint Paris, July 31st, 2025Robust revenue growth+3.4% reported growth to €1,868.3m revenue in half-year 2025, +3.3% organic growth +1.6% organic growth in Q2, c.+3% excluding the impact of the 2024 UEFA Euro and Paris Olympic Games, a record Q2 +12.2% digital revenue growth in half-year 2025, c.40% of Group revenue Strong operating leverage+17.6% Operating Margin at €307.4m 75.8% flow-through rate (conversion of revenue increase to Operating Margin) +11.6% EBIT before impairment charge at €125.6m, +114.7% excluding non-recurring items +10.7% Operating cash flowsGuidance Q3 2025: low single digit negative organic revenue growth expected, taking into account a c.410bp negative comparison impact due to the 2024 Paris Olympic Games and UEFA...

Consistent delivery of SPIE’s growth modelYet another margin step-up: 2025 outlook firmed up Solid first-half results combining 40 bps margin step-up and 5.8% revenue growthRevenue: €4,979m, up +5.8% vs. H1 2024, including +3.8% growth from acquisitions and +2.4% organic growth Sequential improvement in organic growth: +2.6% in Q2, after +2.1% in Q1 Another step-up in EBITA margin: +40 bps to 6.0% in H1 2025 EBITA up +13.2% to €301m Adjusted net income: €166.6m (+5.7% vs. H1 2024)Sustained bolt-on M&A activity, reinforcing leadership in attractive markets3 bolt-on acquisitions signed in 2025 to date, representing €96 million in annual revenue Further expansion into attractive Polish Building Solutions market and high-growth fiber optic services in Switzerland Robust pipeline on highly fragmented marketsStrong financial...